iTeos Therapeutics Announces New  Scientific Advisory Board Members

iTeos Therapeutics Announces New Scientific Advisory Board Members

A2a Inhibitor Clinical Trials Corporate Research TIGIT
Gosselies, Belgium and Cambridge, MA – September 9th, 2019 – iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to…
Read more

Previous news

  • iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer
    Corporate

    iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer

    Gosselies, Belgium and Cambridge, MA – 13 August, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announces the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development. Matthew joins iTeos with 20 years of experience in operational leadership and business development roles, most recently serving as Chief Operating Officer at Endocyte, which was acquired by Novartis for $2.1 billion in 2018. During his 16 year tenure at Endocyte, he had responsibility for all business development and strategic transactions and led a variety of functions including new product planning, marketing and project management. “At iTeos we have built an experienced team that has been hand-picked from across industry to accelerate our efforts of bringing the next generation of immuno-oncology therapies to patients. Matt’s extensive business development background, corporate strategy experience and operational track record is precisely what we need at this stage of our growth and he will be an integral addition to iTeos and the growing executive team,” said Michel Detheux, Ph.D., co-founder, President and Chief Executive Officer of iTeos. “We look forward to his strategic and operational leadership as we advance our pipeline of highly-differentiated immunotherapies through the clinic and we continue to grow our organization.” “I am delighted to join iTeos at such an exciting time as the company advances its key growth initiatives. Our talented staff, highly differentiated pipeline programs, and strong investor base positions iTeos well to transform the treatment paradigm for people living with cancer,” said Matthew Call, Chief Operating Officer of iTeos. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
    Corporate

    iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference

    Gosselies, Belgium and Cambridge, MA – August 7, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 9:45 a.m. ET in New York, NY. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com Amber Fennell, Catherine London, Mathew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics to Present at UBS Global Healthcare Conference
    Corporate

    iTeos Therapeutics to Present at UBS Global Healthcare Conference

    Gosselies, Belgium and Cambridge, MA – May 13, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos, will present at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 11:30 a.m. ET in New York, NY. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in the second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer
    Clinical Trials

    iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer

    First cohort of patients with advanced cancer now dosed with EOS100850 - Target enrollment of 72 patients; initial clinical data expected in Q4 2019 Gosselies, Belgium and Cambridge, MA – April 17, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, announced today the first cohort of patients has been dosed in its Phase 1/1b study with EOS100850, the Company’s investigational A2Areceptor antagonist and lead program candidate. “I am tremendously excited to announce that patient dosing in our innovative, adaptive Phase 1/1b trial is now underway with EOS100850, our unique and specific A2Areceptor antagonist. We believe we have a potential best-in-class compound, which was carefully designed with differentiating features to maximize the therapeutic window,” said Michel Detheux, Ph.D., Co-Founder, President and Chief Executive Officer of iTeos. “The A2A pathway has emerged as one of the most exciting targets due to the emerging clinical evidence validating the important role adenosine plays in suppressing the immune response to cancer in the tumor microenvironment. EOS100850 addresses the therapeutic challenges found within this tumor microenvironment by achieving a higher degree of receptor inhibition with its PK/PD and non-brain penetrant profile and its ability to maintain potent efficacy despite increased levels of adenosine concentrations. We are optimistic that EOS100850 can restore the immune response and may control cancer for patients in multiple indications.”  About the EOS100850 Phase 1/1b Trial This state-of-the-art Phase 1/1b study of EOS100850 will include an extended translational medicine strategy with pre- and post-biopsies, which will enable researchers to identify and confirm relevant biomarkers to be used in further clinical development. Key objectives in this flexible, open-label, dose-escalation study include understanding the safety and tolerability of the compound and determining a recommended Phase 2 dose. The pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity will also be evaluated. The trial will be conducted at multiple clinical sites in Belgium, the United Kingdom and the United States and is expected to enroll 72 patients with advanced cancer. The dose escalation and dose expansion cohorts will include a comprehensive effort to evaluate the activity in specific tumor types as well as to confirm the advantageous PK/PD profile of EOS100850. Disease-specific expansion cohorts will be enrolled at the optimal Phase 2 dose.  For more information on this trial, please visit www.clinicaltrials.gov (Identifier: NCT03873883). About the iTeos Adenosine A2A Receptor Antagonist (EOS100850) The high level of adenosine in the microenvironment of many tumors plays a significant role in tumor immune evasion. The adenosine A2A receptor is the primary adenosine receptor expressed on immune cells. In the presence of adenosine, this receptor suppresses T cell activity. In preclinical studies, EOS100850, iTeos’ A2A receptor antagonist, restores T cell activity and promotes anti-tumor activity in preclinical models, as well as synergizing with several immune-checkpoint inhibitors and chemotherapy. Preliminary evidence of clinical activity has been described in kidney, lung and prostate cancer in clinical studies of A2A receptor antagonists and other agents targeting the adenosine axis. In contrast to other clinical-stage A2A receptor antagonists, EOS100850 retains high potency in the presence of elevated adenosine concentrations measured in the tumor microenvironment and is non-brain penetrant. EOS100850 has been extensively evaluated for safety, efficacy and oral bioavailability in numerous preclinical models. About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in the second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Mathew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iteos@sternir.com

  • iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
    A2a Inhibitor TIGIT

    iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019

    Gosselies, Belgium and Cambridge, MA – March 29, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it will present data on the efficacy of its innovative and differentiated A2A receptor antagonist, EOS100850, as well as its human antibody directed against TIGIT, EOS884448, in eight posters at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2019, taking place from March 29 - April 3, 2019 in Atlanta, Georgia.  “We continue to be excited by the preclinical data from our two immuno-oncology programs, both of which promise mono- and combination therapy potential with other anti-cancer treaments,” said Michel Detheux, President and Chief Executive Officer of iTeos Therapeutics. “The preclinical data being presented at AACR demonstrate key differentiation of our A2A receptor antagonist, such as unique prolonged effects of high potency within the adenosine-rich tumor microenvironment and anti-tumor activity in several cancer models and with different drug combinations. The data also provide a deeper understanding of the adenosine pathway in solid tumors. Additionally, our research on the TIGIT activation pathway sheds light on promising strategies to restore anti-tumor immunity.”  The details of the poster presentations are as follows: Title: EOS100850, a non-brain penetrant highly selective A2A receptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment  Session: Novel Immunomodulatory Agents 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Erica Houthuys, et al. Location: Section 25, Poster 3261 Title: EOS100850 potently restores adenosine A2A receptor-dependent suppression of T cell function in the adenosine rich tumor microenvironment  Session: Novel Immunomodulatory Agents 1  Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Erica Houthuys, et al. Location: Section 25, Poster 3278  Title: Extensive characterization of the adenosine pathway in human solid tumors gives a hint on cancer indication selection for the A2A receptor antagonist EOS100850. Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Veronique Bodo, et al.  Location: Section 25, Poster 4149  Title: EOS100850 inhibits A2A receptor signaling in human whole blood: two pharmacodynamic assays to monitor EOS100850 activity in clinical studies. Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Veronique Bodo, et al. Location: Section 25, Poster 4154 Title: EOS100850, an A2A receptor antagonist with prolonged pharmacodynamic activity, mediates the generation of specific durable immune responses in a murine breast cancer model  Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Grégory Driessens, et al.  Location: Section 25, Poster 4147  Title: EOS884448, a high affinity fully human antibody directed against TIGIT, mediates in vitro anti-tumor activity through multiples mechanisms of action involving activation of intratumor effector cells and depletion of regulatory T cells. Session: Immune Checkpoints 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Catherine Hoofd, et al. Location: Section 24, Poster 3240 Title: a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells  Session: Immune Checkpoints 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET  Authors: Grégory Driessens, et al. Location: Section 24, Poster 3249 Title: TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity Session: Adaptive Immune Cells in the Tumor Microenvironment Date & Time: Wednesday, April 3, 2019, 8:00 AM - 12:00 PM ET  Authors: Catherine Hoofd, et al. Location: Section 23, Poster 4969 Full poster abstracts are available on the AACR conference website at www.aacr.org.  About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com  Amber Fennell, Mathew Neal, Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com   

  • iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer
    Clinical Trials Corporate

    iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer

    Gosselies, Belgium and Cambridge, MA – March 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced the appointment of Joanne Jenkins Lager, M.D., as Chief Medical Officer of iTeos, effective April 1, 2019. “We are extremely pleased to welcome Dr. Lager as our Chief Medical Officer at such an exciting time at iTeos. With our Phase 1 program for our A2A receptor antagonist, EOS100850, underway and our second TIGIT antibody program entering the clinic later this year, we believe our strategic approach has the potential to overcome the significant challenges faced in the immuno-oncology field,” said Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos. “We look forward to benefiting from Joanne’s substantial oncology experience and proven clinical development leadership as we continue to design and develop our next generation immunotherapies to improve the lives of cancer patients worldwide.” Dr. Lager joins iTeos from Sanofi, where she served as Vice President, Head of Global Oncology Development since 2014. In that capacity, she oversaw the development strategy and operations for the company’s early and late-stage clinical development portfolio including both hematologic and solid tumor malignancies. She also served as the co-lead of the Oncology Leadership Team, co-chair of the Therapeutic Area Review Committee and chair of the Oncology Protocol Review Committee. Prior to Sanofi, Dr. Lager served at GlaxoSmithKline in various levels of increasing responsibility, including as Clinical Head of the Cancer Metabolism Discovery Performance Unit. In that capacity, she oversaw the analysis of new targets and undertook early phase clinical studies of oncology drugs. Dr. Lager received her M.D. from Duke University School of Medicine and B.A. in Psychobiology from Wellesley College. “I am joining iTeos as CMO at a transformational stage in the company’s development,” said Joanne Jenkins Lager, M.D., incumbent Chief Medical Officer of iTeos Therapeutics. “I’m excited about the potential of the company’s best-in-class programs to improve treatment for cancer patients.” About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com Amber Fennell, Mathew Neal, Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics to Participate in Upcoming U.S. Conferences in March
    Corporate

    iTeos Therapeutics to Participate in Upcoming U.S. Conferences in March

    Gosselies, Belgium – March 5, 2019 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present in two upcoming U.S. conferences in March.  Cowen & Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 11:30 a.m. ET in Boston, MA. William Blair 9th Annual Cancer Immunotherapy Conference on Thursday, March 21, 2019 at 3:15 p.m. ET in New York, NY.   About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is a best in class adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com  Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com   

  • iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting
    Corporate

    iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting

    Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the presentation of two posters on its novel A2Areceptor antagonist and TIGIT antibody programs, at the upcoming Society for Immunotherapy of Cancer (SITC) 33rdAnnual Meeting, taking place from November 7-11, 2018 in Washington, D.C. “The expanding breadth of knowledge and understanding of the suppressive tumor microenvironment has been  fundamental to the design and development of iTeos’ best-in-class oncology drug candidates,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “The preclinical data presented at SITC demonstrate how our adenosine A2Areceptor antagonist can maintain potency in a high adenosine environment, uniquely evading the limitations faced by repurposed A2Areceptor antagonists. Enabled by the same approach, our TIGIT antagonist monoclonal antibody induces strong anti-tumor efficacy in both monotherapy and in combination with anti-PD1 for more potent activity. We are excited by these findings and look forward to advancing both of these programs into the clinic in the first half of 2019.”  The details of the two presentations are as follows: Title: EOS100850, an insurmountable and non-brain penetrant A2Areceptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and shows best-in class characteristics. Date & Time:Friday, November 9, 2018; 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m. Authors: Houthuys, et al. Poster Number: 667 Key Takeaways: Adenosine levels are elevated in many tumor microenvironments, promoting tumor immune evasion EOS100850 reverses inhibition of immune cell function by potently inhibiting A2A receptor signalling  In both in vitroand in vivotumor models, EOS100850 induces long standing and specific immune protection   Title: Antitumor efficacy of anti-TIGIT antagonist antibody EOS884448 is mediated by a dual mechanism of action involving restoration of T cell effector functions and preferential depletion of Tregs. Date & Time: Saturday, November 10, 2018; 12:45 – 2:15 p.m. and 6:30 – 8:00 p.m. Authors: Hoofd, et al. Poster Number: 666 Key Takeaways: EOS884448 is a fully human, potent and specific disruptor of the immunosuppressive binding of CD155 to TIGIT in the tumor microenvironment Due to its Fc receptor engagement, EOS884448 not only inhibits CD155 binding but also targets for destruction cells that over-express TIGIT (e.g. Tregs) in the tumor microenvironment EOS884448 exhibits efficacy in in vivotumor models and is more effective when combined with other checkpoint inhibitors About iTeos’ Adenosine A2AReceptor Inhibitor (EOS100850) The adenosine A2Areceptor is the main adenosine receptor expressed on immune cells, which promotes immune suppression, leading to tumor evasion. iTeos’ best-in-class A2Areceptor antagonist, EOS100850, restores T-cell activation inhibited by adenosine. EOS100850 promotes anti-tumor efficacy in mouse tumor models in combination with several immune-checkpoint inhibitors, retains high potency in the presence of elevated intra-tumoral adenosine concentrations, and is non-brain penetrant. EOS100850 is currently being evaluated for safety and efficacy in preclinical models. About iTeos’ Human Anti-TIGIT Antibody (EOS884448) TIGIT is an immunosuppressive receptor expressed on lymphoid cell populations. TIGIT expression increases in cancer patients and marks exhausted T cells. EOS884448 is an antagonist antibody against human TIGIT. Preclinical studies show its potency to restore T cell function and to preferentially deplete Treg cells in cancer patient material. ADCC/ADCP-enabling isotypes of a-TIGIT surrogate Ab show potent monotherapy efficacy in murine tumor models that correlates to increased T cell activation and reduced Treg infiltration of tumors. EOS884448 demonstrates classical human IgG pharmacokinetics profile and a good developability profile. EOS884448 is currently being evaluated for safety and efficacy in preclinical models. About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September
    Corporate

    iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September

    Gosselies, Belgium – August 29, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present in two upcoming U.S. conferences in September.  Citi’s 13th Annual Biotech Conference on Wednesday, September 5, 2018 at 11:15 a.m. ET in Boston, MA. Wells Fargo Securities 2018 Healthcare Conference on Thursday, September 6, 2018 at 3:40 p.m. ET in Boston, MA.   About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iteos@sternir.com